Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Financings

Orchestra BioMed Holdings, Inc.

Financings

RaiseDate
Public offering of shares of common stock
Closed: US$80.5M raised · US$5 a share · Piper Sandler +3
Dealers: Piper Sandler (co-lead), TD Cowen (co-lead), BTIG, H.C. Wainwright & Co.
Use of proceeds: Fund AVIM Therapy program and BACKBEAT Trial, Virtue SAB program and Virtue Trial, other R&D, working capital and general corporate purposes
Nov 10, 2026
Public offering of shares of common stock
Announced: Piper Sandler +2
Dealers: Piper Sandler (co-lead), TD Cowen (co-lead), BTIG
Use of proceeds: Fund AVIM Therapy program and BACKBEAT trial, Virtue SAB program and Virtue Trial, other R&D, working capital and general corporate purposes
Nov 5, 2026
Strategic investment of strategic capital
Closed: US$35M raised
Buyers: Medtronic (Medtronic's total capital contribution to Orchestra BioMed is nearly $82 million, including this investment); Ligand (Ligand has now provided $40 million in total capital to the Company)
Aug 10, 2026
Strategic investment of non-voting convertible preferred stock
Announced: US$20M
Buyers: Terumo ($20 million in a new series of non-voting preferred stock)
Use of proceeds: Advance both pivotal stage programs to key clinical and regulatory milestones
Oct 28, 2025
Public offering of common stock and pre-funded warrants
Announced: about US$40M · US$2.75 a share · Piper Sandler +1
Dealers: Piper Sandler (co-lead), TD Cowen (co-lead)
Use of proceeds: Fund AVIM therapy program and BACKBEAT study, Virtue SAB program and trial, other product candidates, working capital and general corporate purposes
Aug 1, 2025
Tiered royalty on future sales of AVIM therapy and Virtue SAB
Announced: US$35M
Buyers: Ligand ($20 million at closing and an additional $15 million at the nine-month anniversary, subject to conditions)
Use of proceeds: To advance its late-stage partnered cardiology programs (AVIM therapy and Virtue SAB)
Jul 31, 2025
Private placement of common stock
Announced: US$5M
Buyers: Ligand ($5 million of common stock)
Jul 31, 2025
Private placement of common stock
Announced: US$10M
Buyers: Medtronic ($10 million of common stock)
Jul 31, 2025
Secured subordinated promissory note convertible to prepaid revenue share
Announced: US$20M
Buyers: Medtronic ($20 million secured subordinated promissory note)
Jul 31, 2025

Read by 6ix AI from the company's releases